Literature DB >> 21116479

Regioselective Palladium-Catalyzed Cross-Coupling Reactions of 2,4,7-Trichloroquinazoline.

Peter Wipf1, Kara M George.   

Abstract

The regioselective palladium-catalyzed cross-coupling reactions of 2,4,7-trichloroquinazoline with various aryl- and heteroarylboronic acids are reported. An efficient, sequential strategy was developed that provides access to novel, functionalized heterocycles.

Entities:  

Year:  2010        PMID： 21116479      PMCID： PMC2992347          DOI： 10.1055/s-0029-1219391

Source DB:  PubMed          Journal:  Synlett        ISSN： 0936-5214            Impact factor:   2.454


  19 in total

1.  Despite concerns, FDA panel backs EGFR inhibitor.

Authors:  Renee Twombly
Journal:  J Natl Cancer Inst       Date:  2002-11-06       Impact factor: 13.506

2.  Molecular features of the prazosin molecule required for activation of Transport-P.

Authors:  Joaquim Fernando Mendes da Silva; Marcus Walters; Saad Al-Damluji; C Robin Ganellin
Journal:  Bioorg Med Chem       Date:  2008-06-25       Impact factor: 3.641

3.  Design, selection, and evaluation of a general kinase-focused library.

Authors:  Hélène Decornez; Anna Gulyás-Forró; Akos Papp; Miklós Szabó; Gabriella Sármay; István Hajdú; Sándor Cseh; György Dormán; Douglas B Kitchen
Journal:  ChemMedChem       Date:  2009-08       Impact factor: 3.466

4.  Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

Authors:  J Baselga; D Rischin; M Ranson; H Calvert; E Raymond; D G Kieback; S B Kaye; L Gianni; A Harris; T Bjork; S D Averbuch; A Feyereislova; H Swaisland; F Rojo; J Albanell
Journal:  J Clin Oncol       Date:  2002-11-01       Impact factor: 44.544

5.  Tyrosine kinases in disease: overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials.

Authors:  L M Strawn; L K Shawver
Journal:  Expert Opin Investig Drugs       Date:  1998-04       Impact factor: 6.206

6.  Catalysts for Suzuki-Miyaura coupling processes: scope and studies of the effect of ligand structure.

Authors:  Timothy E Barder; Shawn D Walker; Joseph R Martinelli; Stephen L Buchwald
Journal:  J Am Chem Soc       Date:  2005-04-06       Impact factor: 15.419

7.  Heteroaromatic thioether-boronic acid cross-coupling under neutral reaction conditions.

Authors:  Lanny S Liebeskind; Jiri Srogl
Journal:  Org Lett       Date:  2002-03-21       Impact factor: 6.005

8.  Quinazolines: combined type 3 and 4 phosphodiesterase inhibitors.

Authors:  B Charpiot; J Brun; I Donze; R Naef; M Stefani; T Mueller
Journal:  Bioorg Med Chem Lett       Date:  1998-10-20       Impact factor: 2.823

9.  Synthesis and biological evaluation of synthetic viridins derived from C(20)-heteroalkylation of the steroidal PI-3-kinase inhibitor wortmannin.

Authors:  Peter Wipf; Daniel J Minion; Robert J Halter; Margareta I Berggren; Caroline B Ho; Gary G Chiang; Lynn Kirkpatrick; Robert Abraham; Garth Powis
Journal:  Org Biomol Chem       Date:  2004-06-14       Impact factor: 3.876

Review 10.  Structure-based design of novel anticancer agents.

Authors:  F M Uckun; E A Sudbeck; C Mao; S Ghosh; X P Liu; A O Vassilev; C S Navara; R K Narla
Journal:  Curr Cancer Drug Targets       Date:  2001-05       Impact factor: 3.428
View more
  2 in total

1.  Synthesis and biological evaluation of a selective N- and p/q-type calcium channel agonist.

Authors:  Mary Liang; Tyler B Tarr; Karla Bravo-Altamirano; Guillermo Valdomir; Gabriel Rensch; Lauren Swanson; Nicholas R DeStefino; Cara M Mazzarisi; Rachel A Olszewski; Gabriela Mustata Wilson; Stephen D Meriney; Peter Wipf
Journal:  ACS Med Chem Lett       Date:  2012-10-01       Impact factor: 4.345

2.  Site-selective Suzuki-Miyaura coupling of heteroaryl halides - understanding the trends for pharmaceutically important classes.

Authors:  Joshua Almond-Thynne; David C Blakemore; David C Pryde; Alan C Spivey
Journal:  Chem Sci       Date:  2016-08-09       Impact factor: 9.825
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.